 |
Regeneron Named Biotechnology Company of the Year
Nov 29, 2012
|
10.4 KB |
|
| |
TARRYTOWN, N.Y., Nov. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it was named "Biotechnology Company of the Year" by Scrip Intelligence at the 8th annual Scrip Awards.
The Award recognizes the biotech firm that has achieved the most in the 12 months between June 1, 2011 and May 31, 2012. In ...
|
|
Regeneron Announces Presentation at the Deutsche Bank 2012 dbAccess BioFEST
Nov 27, 2012
|
9.3 KB |
|
| |
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the Deutsche Bank 2012 dbAccess BioFEST on Monday, December 3, 2012. The presentation is scheduled for 1:05 p.m. Eastern Time. The session may be accessed through the Company's web site, www.regeneron.com, on the 'Events ...
|
|
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Europe
Nov 27, 2012
|
18.7 KB |
|
| |
TARRYTOWN, N.Y., Nov. 27, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). According to the European Medicines Agency (EMA) approv...
|
|
ZALTRAP® (ziv-aflibercept) Receives CHMP Positive Opinion in the European Union for Previously Treated Metastatic Colorectal Cancer
Nov 16, 2012
|
24.3 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Nov. 16, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion and recommended the granting of marketing authorization for ...
|
|
Regeneron Announces November 2012 Investor Conference Presentations
Nov 6, 2012
|
9.7 KB |
|
| |
TARRYTOWN, N.Y., Nov. 6, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:
Lazard Capital Markets 9th Annual Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday, November 13, 2012
Credit Suisse Healthcare Conference at 9:30 a.m. Eas...
|
|
Sanofi and Regeneron Announce Patient Enrollment in Cardiovascular Outcomes Trial with Antibody to PCSK9 for Hypercholesterolemia
Nov 5, 2012
|
21.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Nov. 5, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the ODYSSEY OUTCOMES trial, a Phase 3 cardiovascular outcomes trial (CVOT) with SAR236553/REGN727 is now recruiting patients. SAR236553/REGN727 is an investigational subcutaneously adm...
|
|
Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
Oct 31, 2012
|
19.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Oct. 31, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from a Phase 2 trial of SAR236553/REGN727 in patients with primary hypercholesterolemia were published in the October 31, 2012 issue of the New England Journal of Medicine.
...
|
|
Regeneron Reports Third Quarter 2012 Financial and Operating Results
Oct 24, 2012
|
30.9 KB |
|
| |
TARRYTOWN, N.Y., Oct. 24, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced financial and operating results for the third quarter of 2012 and provided an update on development programs.
The Company reported total revenues of $428 million in the third quarter and $964 million in the first nine months of 2012...
|
|
Regeneron Announces Publication of EYLEA® (aflibercept) Injection Phase 3 VIEW 1 and VIEW 2 Studies in Ophthalmology
Oct 18, 2012
|
18.3 KB |
|
| |
TARRYTOWN, N.Y., Oct. 18, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed one-year results from the VIEW 1 and VIEW 2 Phase 3 studies of EYLEA (aflibercept) Injection were published online in the journal Ophthalmology ahead of a future print publication. The publication can be accessed at http://dig...
|
|
Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012
Oct 10, 2012
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., Oct. 10, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2012 financial and operating results on Wednesday, October 24, 2012, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day.
...
|
|
EYLEA® (aflibercept) Injection Approved for the Treatment of Wet Age-Related Macular Degeneration in Japan
Sep 28, 2012
|
19.9 KB |
|
| |
TARRYTOWN, N.Y., Sept. 28, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that EYLEA® (aflibercept) Injection has received approval for the treatment of patients with neovascular age-related macular degeneration (wet AMD) from the Japanese Ministry of Health, Labour and Welfare (MHLW). In Japan, EYLEA trea...
|
|
Regeneron Announces FDA Approval of EYLEA® (aflibercept) Injection For Macular Edema Following Central Retinal Vein Occlusion
Sep 21, 2012
|
18.3 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Central Retinal Vein Occlusion (CRVO). The recommended dose for EYLEA is 2 milligrams (mg) ever...
|
|
Regeneron Named World's #1 Biopharmaceutical Employer in Science Magazine Annual Survey
Sep 21, 2012
|
10.8 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that Science magazine has ranked Regeneron as the #1 employer in the global biopharmaceutical industry in the journal's annual Top Employers Survey.
"This recognition by Science as the most respected company to work for in the bioph...
|
|
EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Wet Age-Related Macular Degeneration in Europe
Sep 21, 2012
|
18.5 KB |
|
| |
TARRYTOWN, N.Y., Sept. 21, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AM...
|
|
Regeneron Announces September 2012 Investor Conference Presentations
Aug 29, 2012
|
9.7 KB |
|
| |
TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:
Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Tim...
|
|
U.S. FDA Approves ZALTRAP® (ziv-aflibercept) After Priority Review for Previously Treated Metastatic Colorectal Cancer
Aug 3, 2012
|
76.6 KB |
|
| |
PARIS and TARRYTOWN, N.Y., Aug. 3, 2012 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) approved ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLF...
|
|
Regeneron Receives Complete Response Letter From FDA for ARCALYST® (rilonacept) sBLA for the Prevention of Gout Flares in Patients Initiating Uric Acid-lowering Therapies
Jul 30, 2012
|
13.4 KB |
|
| |
TARRYTOWN, N.Y., July 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter for the supplemental biologics license application (sBLA) for ARCALYST® (rilonacept) Injection for Subcutaneous Use for the prevention of gout flares in...
|
|
Regeneron Reports Second Quarter 2012 Financial and Operating Results
Jul 25, 2012
|
29.8 KB |
|
| |
TARRYTOWN, N.Y., July 25, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the second quarter of 2012 and provided an update on development programs.
The Company reported total revenues of $304 million in the second quarter and $536 million in the first half of 2012. T...
|
|
Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
Jul 20, 2012
|
22.2 KB |
|
| |
PARIS and TARRYTOWN, New York, July 20, 2012 /PRNewswire/ --
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that several trials within ODYSSEY, the Phase 3 clinical program of SAR236553/REGN727, have initiated patient enrollment. SAR236553/REGN727 is a potential first-in-class, subcut...
|
|
Regeneron to Report Second Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on July 25, 2012
Jul 11, 2012
|
9.5 KB |
|
| |
TARRYTOWN, N.Y., July 11, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2012 financial and operating results on Wednesday, July 25, 2012, before the U.S. financial markets open. The Company will host a conference call at 8:30 AM EDT that day.
Live audio of the con...
|
|
|
Shareholder Briefcase
E-mail Alerts
Download Library
REGN Snapshot
RSS News Feeds